- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07223203
TRITON-PN: Een onderzoek naar de werkzaamheid en veiligheid van Nucresiran bij patiënten met erfelijke transthyretine-amyloïdose met polyneuropathie (TRITON-PN)
TRITON-PN: Een fase 3, wereldwijd, gerandomiseerd, open-label onderzoek naar de werkzaamheid en veiligheid van Nucresiran bij patiënten met erfelijke transthyretine-gemedieerde amyloïdose met polyneuropathie (hATTR-PN)
The purpose of this study is to:
- Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
- Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Clinical Trial Information Line
- Telefoonnummer: 1-877-ALNYLAM
- E-mail: clinicaltrials@alnylam.com
Studie Contact Back-up
- Naam: Clinical Trial Information Line
- Telefoonnummer: 1-877-256-9526
- E-mail: clinicaltrials@alnylam.com
Studie Locaties
-
-
-
Belgrano, Argentinië, C1428AQK
- Werving
- Clinical Trial Site
-
Rosario, Argentinië, CP2000
- Werving
- Clinical Trial Site
-
-
-
-
-
Darlinghurst, Australië, 2010
- Werving
- Clinical Trial Site
-
Woolloongabba, Australië, 4102
- Werving
- Clinical Trial Site
-
-
-
-
-
Ribeirão Preto, Brazilië, 14051-140
- Werving
- Clinical Trial Site
-
Rio de Janeiro, Brazilië, 22640-100
- Werving
- Clinical Trial Site
-
Rio de Janeiro, Brazilië, 22775-001
- Werving
- Clinical Trial Site
-
Salvador, Brazilië, 40290-000
- Werving
- Clinical Trial Site
-
São Paulo, Brazilië, 04038-002
- Werving
- Clinical Trial Site
-
-
-
-
-
Vancouver, Canada, V5Z 1M9
- Werving
- Clinical Trial Site
-
-
-
-
-
Égkomi, Cyprus, 2371
- Werving
- Clinical Trial Site
-
-
-
-
-
Berlin, Duitsland, 10117
- Werving
- Clinical Trial Site
-
Heidelberg, Duitsland, 69120
- Werving
- Clinical Trial Site
-
Münster, Duitsland, 48149
- Werving
- Clinical Trial Site
-
-
-
-
-
Créteil, Frankrijk, 94000
- Werving
- Clinical Trial Site
-
Le Kremlin-Bicêtre, Frankrijk, 94270
- Werving
- Clinical Trial Site
-
Marseille, Frankrijk, 13005
- Werving
- Clinical Trial Site
-
-
-
-
-
Athens, Griekenland, 115 28
- Werving
- Clinical Trial Site
-
Heraklion, Griekenland, 715 00
- Werving
- Clinical Trial Site
-
-
-
-
-
Dublin, Ierland, D24 NR0A
- Werving
- Clinical Trial Site
-
-
-
-
-
Florence, Italië, 50134
- Werving
- Clinical Trial Site
-
Milan, Italië, 20133
- Werving
- Clinical Trial Site
-
Padova, Italië, 35128
- Werving
- Clinical Trial Site
-
Pavia, Italië, 27100
- Werving
- Clinical Trial Site
-
Roma, Italië, 00168
- Werving
- Clinical Trial Site
-
-
-
-
-
Bunkyo C, Japan, 113-8519
- Werving
- Clinical Trial Site
-
Kumamoto, Japan, 860-8556
- Werving
- Clinical Trial Site
-
Matsumoto-shi, Japan, 390-8621
- Werving
- Clinical Trial Site
-
Suita, Japan, 565-0871
- Werving
- Clinical Trial Site
-
-
-
-
-
Kuala Lumpur, Maleisië, 59100
- Werving
- Clinical Trial Site
-
-
-
-
-
Guadalajara, Mexico, 44670
- Werving
- Clinical Trial Site
-
Tlalpan, Mexico, 14080
- Werving
- Clinical Trial Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Werving
- Clinical Trial Site
-
Porto, Portugal, 4099-001
- Werving
- Clinical Trial Site
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Clinical Trial Site
-
Huelva, Spanje, 21005
- Werving
- Clinical Trial Site
-
L'Hospitalet de Llobregat, Spanje, 8907
- Werving
- Clinical Trial Site
-
Madrid, Spanje, 28040
- Werving
- Clinical Trial Site
-
Palma de Mallorca, Spanje, 07198
- Werving
- Clinical Trial Site
-
-
-
-
-
Taipei, Taiwan, 10002
- Werving
- Clinical Trial Site
-
Taipei, Taiwan, 112
- Werving
- Clinical Trial Site
-
Taoyuan City, Taiwan, 33305
- Werving
- Clinical Trial Site
-
-
-
-
-
Istanbul, Turkije (Türkiye), 34093
- Werving
- Clinical Trial Site
-
Izmir, Turkije (Türkiye), 35330
- Werving
- Clinical Trial Site
-
-
-
-
-
London, Verenigd Koninkrijk, NW3 2QG
- Werving
- Clinical Trial Site
-
-
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Clinical Trial Site
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Werving
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02118
- Werving
- Clinical Trial Site
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Clinical Trial Site
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Werving
- Clinical Trial Site
-
New York, New York, Verenigde Staten, 10016
- Werving
- Clinical Trial Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Verenigde Staten, 27514
- Werving
- Clinical Trial Site
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Clinical Trial Site
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75246
- Werving
- Clinical Trial Site
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Clinical Trial Site
-
-
-
-
-
Seoul, Zuid -Korea, 06351
- Werving
- Clinical Trial Site
-
Seoul, Zuid -Korea, 05030
- Werving
- Clinical Trial Site
-
-
-
-
-
Stockholm, Zweden, 113 61
- Werving
- Clinical Trial Site
-
Umeå, Zweden, 907 37
- Werving
- Clinical Trial Site
-
-
-
-
-
Bern, Zwitserland, 3010
- Werving
- Clinical Trial Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has documented diagnosis of hATTR-PN
- Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
- Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
- Has a Karnofsky Performance Status (KPS) of ≥60%
Exclusion Criteria:
- Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
- Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
- Has a New York Heart Association (NYHA) heart failure classification >2
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
- Has total bilirubin >1.5 ULN
- Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
- Has other known causes of sensorimotor or autonomic neuropathy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Nucresiran 300 mg
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andere namen:
|
|
Actieve vergelijker: Vutrisiran 25 mg followed by Nucresiran 300 mg
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period |
Nucresiran 300 mg administered SC q6M
Andere namen:
Vutrisiran 25 mg administered SC q3M
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tijdsspanne: Baseline and Month 9
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 9
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage reductie in serum TTR-niveaus in de Nucresiran-groep vergeleken met de in-onderzoek Vutrisiran-groep tot en met maand 9
Tijdsspanne: Tot maand 9
|
Tot maand 9
|
|
|
Percentage reductie in serum TTR-niveaus in de nucresiran-groep vergeleken met de in-studie vutrisiran-groep tot en met maand 18
Tijdsspanne: Tot maand 18
|
Tot maand 18
|
|
|
Percentage reductie in TTR-serumniveaus in de Nucresiran-groep vergeleken met de in-studie Vutrisiran-groep bij week 6
Tijdsspanne: Week 6
|
Week 6
|
|
|
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tijdsspanne: Baseline and Month 9
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 9
|
|
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tijdsspanne: Baseline and Month 9
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 9
|
|
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tijdsspanne: Baseline and Month 18
|
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tijdsspanne: Baseline and Month 18
|
The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome. |
Baseline and Month 18
|
|
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tijdsspanne: Baseline and Month 18
|
The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome. |
Baseline and Month 18
|
|
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tijdsspanne: Baseline and Month 18
|
The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability. |
Baseline and Month 18
|
|
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tijdsspanne: Baseline and Month 18
|
The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening. |
Baseline and Month 18
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Medical Director, Alnylam Pharmaceuticals
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- ALN-TTRSC04-004
- 2025-522544-40-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Phase 2-4 trials:
Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.
Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.
Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .